middle.news
SomnoMed Surges 23% in Q3 Revenue, Tackles US Tariff Hurdles
2:53pm on Wednesday 30th of April, 2025 AEST
•
Healthcare
Read Story
SomnoMed Surges 23% in Q3 Revenue, Tackles US Tariff Hurdles
2:53pm on Wednesday 30th of April, 2025 AEST
Key Points
Q3 FY25 revenue rose 23.2% to $27.7 million
Cash balance strengthened to $18.7 million
Full-year FY25 guidance reconfirmed: ~$105 million revenue, $7–9 million EBITDA
Company pursuing Nairobi Protocol exemption to mitigate US tariffs
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Somnomed (ASX:SOM)
OPEN ARTICLE